EGFR and non-small cell lung carcinoma: Furthermore, it has been reported that there is a significant correlation between expression of E-cadherin and sensitivity to the EGFR tyrosine kinase inhibitor, gefitinib, in non-small cell lung cancer cell lines (41), and that the most gefitinib-sensitive cell lines have higher levels of EGFR activation (42).